Le Lézard
Classified in: Health, Science and technology, Business
Subjects: FNC, ACC

Lima Corporate Announces Closing Of ? 275 Million Senior Secured Notes Due 2023


SAN DANIELE DEL FRIULI, Italy, November 2, 2017 /PRNewswire/ --

Lima Corporate announces the closing of ? 275,000,000 aggregate principal amount of its Senior Secured Notes due 2023. The Notes bear interest at a rate of E+3.75 % per year, with a 0.00 % EURIBOR floor - a benchmark issuance among comparable companies - and are listed on the Euro MTF Market of the Luxembourg Stock Exchange as well as on the Extra MOT Pro Segment of the Italian Stock Exchange. In connection with the refinancing, Lima Corporate also entered into a ? 60 million super senior revolving credit facility. The net proceeds from the offering were used to repay in full Lima Corporate's and its subsidiaries' outstanding indebtedness under the existing senior facilities agreement.  

     (Logo: http://photos.prnewswire.com/prnh/20150417/739765 )

"The refinancing provides Lima Corporate with greater flexibility to fuel future growth and support its strategic plans.  We have also gained leverage for potential M&A activities," commented Luigi Ferrari, CEO of Lima Corporate. Net leverage at closing corresponded to 5.5x Lima Corporate's Adjusted EBITDA for the twelve months ended March 31st, 2017.

Lima Corporate operates 24 subsidiaries worldwide and is present in 47 countries through a comprehensive network of direct and indirect sales forces and maintains three state-of-the-art production sites in Italy, employing over 800 people globally.

About Lima Corporate 

Lima Corporate is a global medical device company providing reconstructive orthopedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, Lima Corporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. Lima Corporate's product range includes large joint revision and primary implants and complete extremities solutions including fixation.

The company routinely posts important information for Investors on its website within the 'Investors' section.

Please visit us on: https://www.limacorporate.com/aboutus.html?b=investors&lang=en

Limacorporate S.p.A.
Via Nazionale, 52
33038 Villanova di San Daniele
Udine - Italy
T: +39-0432-945511
E: [email protected]

SOURCE Limacorporate S.p.A.


These press releases may also interest you

at 15:05
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual...

at 15:00
Beghou Consulting announced Thursday several additions to its executive team to support the company's technology innovation, product development and growth initiatives. Dan Cardinal, a Partner at Beghou, will become Chief Technology Officer. The...

at 15:00
Urban Wellness Group, a pioneering wellness provider, is proud to announce its official launch of new anti-aging and sleep enhancement treatments to southeast Portland. Dr. Jason Zabell and Dr. Andy Swanson set themselves apart by pairing over 30...

at 14:55
Peninsula Canada, a global leading HR and health & safety firm, committed to making a positive impact in the community, is proud to announce a partnership with SickKids Foundation, a leading charity dedicated to supporting The Hospital for Sick...

at 14:30
The "Global Immunoprecipitation Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029" report has been added to  ResearchAndMarkets.com's offering. The Global Immunoprecipitation Testing Market size is estimated...

at 14:25
Regulatory News: POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and...



News published on and distributed by: